Company Filing History:
Years Active: 2016-2025
Title: Christopher S Regens: Innovator in MCL1 Inhibitors
Introduction
Christopher S Regens is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the development of MCL1 inhibitors. With a total of 8 patents to his name, Regens has established himself as a key figure in the pharmaceutical industry.
Latest Patents
Regens' latest patents focus on processes and intermediates for preparing MCL1 inhibitors. The first patent provides methods for preparing MCL1 inhibitors or a salt thereof, along with related key intermediates. The second patent relates to methods and intermediates for the synthesis of certain compounds that inhibit MCL1, aimed at treating various cancers. These innovations are crucial for advancing cancer treatment options.
Career Highlights
Throughout his career, Christopher S Regens has worked with leading companies in the pharmaceutical sector, including Gilead Sciences, Inc. and Bristol-Myers Squibb Company. His experience in these organizations has allowed him to contribute to groundbreaking research and development efforts.
Collaborations
Regens has collaborated with notable professionals in his field, including Michael A Ischay and Jeffrey E Merit. These partnerships have further enhanced his work and the impact of his inventions.
Conclusion
Christopher S Regens is a distinguished inventor whose work on MCL1 inhibitors is paving the way for new cancer therapies. His contributions to the pharmaceutical industry are invaluable and continue to influence the field of medicinal chemistry.